DOCSLIB.ORG

Ron Kopito Stanford University Brenda Schulman 18 - 22 January 2010 (Mon - Fri) St Jude’S Children Research Hospital

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ron Kopito Stanford University Brenda Schulman 18 - 22 January 2010 (Mon - Fri) St Jude’S Children Research Hospital Institute for Advanced Study Aaron Ciechanover Workshop on Nobel Laureate in Chemistry Technion - Israel Institute of Technology Visiting Member, HKUST Institute for Advanced Study Ubiquitin System and Michael Karin University of California at San Diego Pathogenesis of Diseases Ron Kopito Stanford University Brenda Schulman 18 - 22 January 2010 (Mon - Fri) St Jude’s Children Research Hospital Lectures 9:00 am - 12:00 noon Seminars 2:00 pm - 3:30 pm Sze-Yuen Chung Council Chamber (7/F via Lifts 13-15) Padma and Hari Harilela Lecture Theater (LT-C) 18 Jan “The Ubiquitin Proteolytic System: Historical Overview, “On the Regulation of the Regulators or How the (Mon) Mechanisms of Action, Involvement in Human Diseases, Ubiquitin System Components are Degraded” and Drug Targeting” by Aaron Ciechanover by Aaron Ciechanover 19 Jan “Structural Biology of the Ubiquitin System: Getting “Dynamic Mechanisms of Ubiquitin Conjugation” (Tue) Ubiquitin onto Targets” by Brenda Schulman by Brenda Schulman 20 Jan “Structural Biology of the Ubiquitin System: After “Dissection of the Endoplasmic Reticulum Associated (Wed) Ubiquitination” by Brenda Schulman Degradation (ERAD) System in Mammalian Cells” “Human Diseases and Drug Targeting of the Ubiquitin by Ron Kopito System” by Aaron Ciechanover 21 Jan “Protein Quality Control and the Ubiquitin Proteasome “Impaired Function of the Ubiquitin-Proteasome (Thu) System in Neurodegenerative Disease” by Ron Kopito Pathway in Huntington’s Disease” by Ron Kopito 22 Jan “The Regulation of NF-␬B by Protein Ubiquitination: “Differential TRAF3 Ubiquitination Determines the (Fri) From Biochemistry to Biology” by Michael Karin Outcome of TLR Signaling” by Michael Karin Enquiries: [email protected]/2358 8424 Co-organized with 3437 Department of Biochemistry and PTC-G1 http://ias.ust.hk Molecular Neuroscience Center Institute for Advanced Study Seminars Ubiquitin System and Pathogenesis of Diseases 18 – 22 January 2010 2:00 – 3:30 pm Padma and Hari Harilela Lecture Theater (LT-C), HKUST 18 Jan (Mon) “On the Regulation of the Regulators or How the Ubiquitin System Components are Degraded” Dr. Aaron Ciechanover (Nobel Laureate in Chemistry) Technion – Israel Institute of Technology Aaron Ciechanover was born in Haifa, Israel in 1947. He is a Distinguished Research Professor in the Technion - Israel Institute of Technology in Haifa. He received his M.Sc. (1971) and M.D. (1975) from the Hebrew University in Jerusalem, and his D.Sc. (1982) from the Technion. There, as a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, they discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. They deciphered the mechanism of conjugation, described the general proteolytic functions of the system, and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease. As a post doctoral fellow with Dr. Harvey Lodish at the M.I.T., he continued his studies on the ubiquitin system and made additional important discoveries. Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Consequently, the system has become an important platform for drug development. Among the numerous prizes Ciechanover received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose). Among many esteemed bodies, Ciechanover is member of the Israeli Academy of Sciences and Humanities, the USA National Academy of Sciences and its Institute of Medicine (Foreign Associate), the American Philosophical Society, and the American Academy of Arts and Sciences (Foreign Fellow). IAS Seminars Ubiquitin System and Pathogenesis of Diseases 19 Jan (Tue) “Dynamic Mechanisms of Ubiquitin Conjugation” Brenda Schulman St Jude Children’s Research Hospital Brenda Schulman is an Investigator of the Howard Hughes Medical Institute, and a Full Member in the Departments of Structural Biology and Genetics/Tumor Cell Biology at St. Jude Children’s Research Hospital. She is also Co-Director of the Program in Molecular Oncology at the St. Jude Cancer Center, and holds affiliate faculty positions at the University of Tennessee College of Medicine and Vanderbilt University. Schulman received her bachelor’s degree in Biology from the Johns Hopkins University in 1989. Following obtaining her Ph.D. in Biology from M.I.T. in 1996, she did postdoctoral studies in cell cycle research at Massachusetts General Hospital, and in X-ray crystallography at Memorial Sloan-Kettering Cancer Center. She has received a Pew Scholar Award in the Biomedical Sciences, a Beckman Young Investigator Award, and a U.S. Presidential Early Career Award for Scientists and Engineers. Her current research is focused on understanding the conjugation pathways for ubiquitin and ubiquitin-like proteins, and on the roles of these pathways in controlling cell division. 20 & 21 Jan (Wed & Thu) “Dissection of the Endoplasmic Reticulum Associated Degradation (ERAD) System in Mammalian Cells” “Impaired Function of the Ubiquitin-Proteasome Pathway in Huntington’s Disease” Ron Kopito Stanford University Ron R. Kopito received his A.B. from Bowdoin College in 1976 and his Ph.D. from the Massachusetts Institute of Technology (MIT) in 1982. He was a Postdoctoral Fellow with Harvey Lodish at the Whitehead Institute at MIT from 1982-1987. Since 1987 he has been on the faculty of Stanford University where is currently a Professor in the Department of Biology. His is a recipient of many awards, including appointments as a Lucille P. Markey Scholar (1985-1991) a Presidential Young Investigator (1989-1994) an Established Investigator of the American Heart Association. He has served or is serving on the editorial boards of the Journal of Biological Chemistry, the Journal of Cell Sciences, the Journal of Membrane Biology and Autophagy. Research in Professor Kopito’s lab is focused on understanding the cellular ‘quality control’ mechanisms that monitor protein folding and assembly in mammalian cells, and the role of these processes in the prevention of human disease. IAS Seminars Ubiquitin System and Pathogenesis of Diseases 22 Jan (Fri) “Differential TRAF3 Ubiquitination Determines the Outcome of TLR Signaling” Michael Karin University of California at San Diego Michael Karin received his BSc in Biology in 1975 at Tel Aviv University, Tel Aviv, Israel and his PhD in Molecular Biology in 1979, University of California, Los Angeles. Dr. Karin is currently a Distinguished Professor of Pharmacology and Pathology at the School of Medicine, University of California, San Diego, where has been on the faculty since 1987. He was a cofounder of Signal Pharmaceutical (currently Celgene) and had served as a member of the Scientific Advisory Board of the Signal Research Division of Celgene. Dr. Karin also served as a member of the National Advisory Council for Environmental Health Sciences and has been an American Cancer Society Research Professor since 1999 and a member of the US National Academy of Sciences since 2005. He is a leading world authority on signal transduction pathways that regulate gene expression in response to extracellular stimuli, infection and stress. Key achievements include definition of cis elements that mediate gene induction by hormones, cytokines and stress, identification and characterization of the transcription factors that recognize these elements and the protein kinase cascades that regulate their activities. Much of Dr. Karin’s current activity is focused on understanding the link between inflammation, cancer and metabolic disease as well as on understanding the signaling mechanisms used by receptors involved in inflammation (TNF receptors) and innate immunity (TLR2 and NLRs). He has published over 300 scientific articles and is an inventor on over 25 different patents or pending patent applications. Recently, Dr Karin was ranked first worldwide by the Institute of Scientific Information (ISI) in a recent listing of most-cited molecular biology and genetic research papers published in prestigious journals..
Load more

Recommended publications
  • System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes
    System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes Wei Zhang1,11, Kuen-Phon Wu2,11, Maria A. Sartori1, Hari B. Kamadurai2, Alban Ordureau3, Chong Jiang4, Peter Y. Mercredi2, Ryan Murchie4, Jicheng Hu5, Avinash Persaud4, Manjeet Mukherjee2, Nan Li6, Anne Doye7, John R. Walker5, Yi Sheng8, Zhenyue Hao9, Yanjun Li5, Kevin R. Brown1, Emmanuel Lemichez7, Junjie Chen6, Yufeng Tong5,10, J. Wade Harper3, Jason Moffat1,12, Daniela Rotin4,12, Brenda A. Schulman2,12 * and Sachdev. S. Sidhu1,12 * 1Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, 160 College Street, Toronto, Ontario M5S3E1, Canada 2Department of Structural Biology and Tumor Cell Biology, Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, TN 38105, USA 3Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA 4Program in Cell Biology, Hospital for Sick Children, and Department of Biochemistry, University of Toronto, Toronto, Ontario M5G 0A4, Canada 5Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G1L7, Canada 6Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA 7Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Université de Nice-Sophia Antipolis, 151 Route St Antoine de Ginestière, BP 2 3194, 06204 Nice Cedex, France. 8Department of Biology, York University, Toronto, Ontario M3J1P3, Canada 9Campbell Family Cancer Research Institute, University Health Network, Toronto, Ontario M5G2C1, Canada 10Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5G1L7, Canada 11Co-first author 12Co-senior author *To whom correspondence should be addressed. E-mail: [email protected] (B.A.S.) and [email protected] (S.S.S).
    [Show full text]
  • Press Release, February 12, 2020 in the Right Place at the Right Time
    public relations Press Release, February 12, 2020 dr. christiane menzfeld phone: +49 89 8578-2824 [email protected] www.biochem.mpg.de/news @MPI_Biochem In the right place at the right time Scientists at the Max Planck Institute of Biochemistry (MPIB) decipher the activation chain of protein degradation Proteins are molecular work horses in the cell that perform specific tasks, but it is essential that the timing of protein activities is exquisitely controlled. When proteins have fulfilled their tasks, degradation of these proteins will end processes that are unneeded or detrimental. To control timing, a label – called “ubiquitin” - is attached to unwanted proteins, marking the protein for degradation. Although complex molecular machineries were known to attach ubiquitin, how these machines carry out the labeling process was unknown. Researchers at MPIB, in collaboration with the University of Nevada Las Vegas, have revealed these mechanisms and published the results in the journal Nature. Numerous cellular processes such as immune responses or cell multiplication depend on many different proteins working in sequence. In order for the cell to function correctly, proteins must be degraded after their work is done. When disease-causing mutations block timely protein degradation, proteins could function at the wrong time, which can lead to diseases, including cancers, heart diseases and developmental disorders. Controlling protein degradation Cells “know” to break down proteins by marking unwanted proteins for degradation with another protein called "ubiquitin". The labelling process, known as ubiquitylation, is carried out by molecular machines, called E3 ligases. It is important that the E3 ligases themselves are switched on and off in the cells at the right place and at the right time.
    [Show full text]
  • Prof. Dr. Brenda Schulman Ft
    Research Interests – Prof. Dr. Brenda Schulman Ft Proteins are the workhorses of cells. Some proteins play structural roles, for example serving as architectural frameworks underlying cell shape; other proteins are enzymes that synthe- sise and break down sugars, fats, and other types of molecules needed for cellular metabo- lism; some proteins have motor domains to achieve movement, for example untangling com- plicated macromolecular assemblies or transporting cargoes to precise locations within cells. The staggering array of protein functions vastly exceeds the number of different proteins en- coded by an organism’s genome (e.g., roughly 20,000 different proteins can be made from scratch in human cells). To meet cellular demands and establish regulation, the structures and functions of pre-existing proteins can be transformed in innumerable ways by post-trans- lational modification. A predominant set of modifications involves covalent linkage of ubiquitin (UB) and members of the family of ubiquitin-like proteins (UBL). We study molecular princi- ples, cellular pathways, and biological roles of regulation by UB and UBL. This is of broad im- portance for understanding numerous biological processes, and for deciphering signalling pathways and their roles in diseases. The UB/UBL system is truly remarkable in that it involves the physical linkage of entire pro- teins onto other proteins. With more than 1000 atoms, each UB and UBL is a relatively mas- sive modification that can profoundly affect the chemical and physical properties of its tar- gets. There is great diversity in the system, with more than a dozen different UBL in human cells. Furthermore, UB and some UBL become linked to each other in “chains” with different linkages defined by the amino acids connecting one UB (or UBL) and the next in the chain.
    [Show full text]
  • Structural Insights Into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation
    Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation David M. Duda,1,2,4 Laura A. Borg,2,4 Daniel C. Scott,1,2,4 Harold W. Hunt,2 Michal Hammel,3 and Brenda A. Schulman1,2,* 1Howard Hughes Medical Institute 2Departments of Structural Biology and Genetics/Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA 3Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA 4These authors contributed equally to this work *Correspondence: [email protected] DOI 10.1016/j.cell.2008.07.022 SUMMARY Knipscheer and Sixma, 2007). In humans, UBL ligation is catalyzed by 600 potential E3s (Li et al., 2008). E3 activity is Cullin-RING ligases (CRLs) comprise the largest generally regulated by posttranslational modifications such as ubiquitin E3 subclass, in which a central cullin phosphorylation, hydroxylation, processing, or UBL attachment. subunit links a substrate-binding adaptor with an The largest E3 subclass consists of modular, multisubunit E2-binding RING. Covalent attachment of the ubiqui- Cullin-RING ligases (CRLs) (Cardozo and Pagano, 2004; Petroski tin-like protein NEDD8 to a conserved C-terminal and Deshaies, 2005). Human CRL cores contain a cullin (Cul1, 2, domain (ctd) lysine stimulates CRL ubiquitination ac- 3, 4A, 4B, 5) and Rbx/Roc1 or 2 and adopt an elongated archi- tecture with substrate- and E2-binding sites at opposite ends tivity and prevents binding of the inhibitor CAND1. (Zheng et al., 2002b). At one end, a cullin’s N-terminal domain Here we report striking conformational rearrange- ctd (ntd) can pair with up to hundreds of substrate-binding adaptors.
    [Show full text]
  • Title: Rub1/NEDD8, a Ubiquitin-Like Modifier, Is Also a Ubiquitin Modifier
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.18.159145; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Rub1/NEDD8, a ubiquitin-like modifier, is also a ubiquitin modifier Authors: Sylvia Zerath Gurevich1, Abhishek Sinha3, Joseph Longworth5, Rajesh K. Singh2, Betsegaw E. Lemma2, Anita Thakur1, Oliver Popp4, Daniel Kornitzer6, Noa Reis1, Martin Scheffner7, Gunnar Dittmar4,5, Elah Pick3, David Fushman2, Michael H. Glickman1*. 1Faculty of Biology, Technion Israel Institute of Technology, Haifa 32000 Israel, 2Department of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742, USA, 3Department of Biology and Environment, University of Haifa at Oranim, Tivon 36006, Israel, 4Max-Delbruck Center, Berlin Germany, 5LIH Luxemburg, 6Faculty of Medicine, Technion-IIT, Haifa 32000 Israel, 7Department of Biology - Universität Konstanz, Germany *To whom correspondence should be addressed. Running title: Rub1 modifies ubiquitin Key words Ubiquitin, polyubiquitin, Rub1, NEDD8, Ubiquitin-like (UBL), CULLIN, Cullin-related ligases (CRL), protein post-translational modifications (PTMs) bioRxiv preprint doi: https://doi.org/10.1101/2020.06.18.159145; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Rub1 modifies ubiquitin ABSTRACT Of all ubiquitin-like small protein modifiers, Rub1/NEDD8 is the closest kin of ubiquitin in sequence and in structure. Despite their profound similarities, prevalence of ubiquitin and of Rub1 is starkly different: targets of ubiquitin modification reach into the thousands, whereas unique targets of Rub1/NEDD8 appear limited to one family of proteins, Cullins.
    [Show full text]
  • AWARD SYMPOSIUM of the 2017 HEINRICH WIELAND PRIZE Nymphenburg Palace, Munich, Germany Thursday, October 19, 2017
    2017HEINRICH WIELAND PRIZE AWARD SYMPOSIUM OF THE 2017 HEINRICH WIELAND PRIZE Nymphenburg Palace, Munich, Germany Thursday, October 19, 2017 THE PRIZE HEINRICH WIELAND PRIZE The international Heinrich Wieland Prize honours distinguished scientists for their outstanding research on biologically active molecules and systems in the fields of chemistry, biochemistry, and physiology as well as their clinical importance. The prize is endowed with 100,000 euros by the Boehringer Ingelheim Foundation and named after Heinrich Wieland (1877–1957), Nobel Laureate in Chemistry in 1927. Every year, the foundation invites scientists to make nominations in an open call. It entrusts the selection of the awardees to a scientific Board of Trustees, all of whom work in an honorary capacity (see page 7 for current members). Presented annually since 1964, the Heinrich Wieland Prize has four subsequent Nobel Laureates among its awardees. www.heinrich-wieland-prize.de 2 PROGRAMME AWARD SYMPOSIUM 3:30 P.M. Registration 4:00 P.M. Welcome and opening remarks Professor Dr Felix Wieland, Chair of the Board of Trustees of the Heinrich Wieland Prize, University of Heidelberg, Heidelberg, Germany 4:10 P.M. “Protein folding homeostasis in the endoplasmic reticulum” Professor David Ron, MD, University of Cambridge, Cambridge, UK 4:50 P.M. “Twists and turns in ubiquitin conjugation” Professor Brenda A. Schulman, PhD, Max Planck Institute of Biochemistry, Martinsried, Germany 5:30 P.M. Coffee break including “Meet the Speakers” for selected students 6:10 P.M. “Editing of ubiquitin chains” Professor Daniel Finley, PhD, Harvard Medical School, Boston, MA, USA 6:50 P.M. Award ceremony Moderated by Dr Claudia Walther, Managing Director of the Boehringer Ingelheim Foundation, Mainz, Germany Musical Introduction Wolfgang Amadeus Mozart (1756–1791): String Quartet in C major, KV 465, Mov.
    [Show full text]
  • Illuminating a Ubiquitin Transfer Relay, Step-By-Step
    IFOM: A YEAR IN REVIEW 2013 Illuminating a ubiquitin transfer relay, step-by-step Commentary on Simona Polo’s paper published on Nature Structural & Molecular Biology by Brenda A. Schulman A key way that protein activities are controlled in work on this question from different directions. a spatiotemporal manner is by post-translational I have long been interested in the biochemical modification, such as by covalent ligation of and structural basis by which ubiquitin becomes the small protein ubiquitin. In some cases, a attached to targets to regulate function. For over single monoubiquitin is attached. Alternatively, a dozen years, Simona Polo has been a leader repeated rounds of ubiquitin ligation can form in understanding numerous facets of ubiquitin polyubiquitin chains with multiple ubiquitin signaling, although her path started with a quest molecules attached to each other. Chains can form to decipher regulation of and by the epidermal on several different sites of ubiquitin. growth receptor. In seminal work performed initially with Pier Paolo Di Fiore, and then later Initially, polyubiquitin chains were mainly in her own lab, Simona found that Kay Hofmann’s known for mediating interactions with the predicted ubiquitin interacting motif (UIM) proteasome and directing degradation of the sequence in epsin family endocytic regulators modified protein. However, it is now known that both binds monoubiquitin, and is also responsible chains linked via lysine 63 on ubiquitin (“K63- for Eps15 monoubiquitination. Simona’s lab linked chains”) regulate diverse functions such discovered a novel mechanism termed “coupled as protein trafficking, DNA repair, and immune monoubiquitination”, where Eps15 uses its UIM signaling.
    [Show full text]
  • Curriculum Vitae Prof. Dr. Brenda A. Schulman
    Curriculum Vitae Prof. Dr. Brenda A. Schulman Name: Brenda A. Schulman Born: 18 June 1967 Research priorities: Biochemistry, structural biology, post-translational modifications, ubiquitin, protein degradation, cell cycle, autophagy Brenda A. Schulman is a biochemist, structural biologist, and cell biologist. Her lab elucidates fundamental principles underlying cellular regulation by small proteins known as ubiquitin and ubiquitin-like proteins. Because this regulation is associated with numerous diseases - including cancers, neurodegenerative disorders, and viral infections - Schulman’s research enables deciphering physiologically important signaling pathways and their roles in diseases. Academic and professional career since 2018 Honorary Professor, Department of Chemistry, Technical University of Munich, Germany since 2017 Director and Scientific Member at the Max Planck Institute of Biochemistry (primary appointment) Martinsried, Germany since 2017 Adjunct Faculty, St. Jude Children’s Research Hospital, Memphis, USA 2016 Director, Department of Molecular Machines and Signaling, Max-Planck-Institute of Biochemistry, Martinsried/Munich, Germany (secondary appointment) 2005 - 2017 Investigator, Howard Hughes Medical Institute, Chevy Chase, USA 2001 - 2017 Faculty, St. Jude Children’s Research Hospital, Memphis, USA 1998 - 2001 Postdoctoral fellow, Memorial Sloan-Kettering Cancer Center, New York, USA (Advisor: Nikola P. Pavletich) 1996 - 1998 Postdoctoral fellow, Massachusetts General Hospital Cancer Center, Boston, USA (Advisor: Ed
    [Show full text]
  • Press Release, September 25, 2019 Brenda Schulman Becomes New
    public relations Press Release, September 25, 2019 dr. christiane menzfeld phone: +49 89 8578-2824 [email protected] www.biochem.mpg.de/news @MPI_Biochem Brenda Schulman becomes new Leopoldina Member Brenda Schulman, head of the department "Molecular Machines and Signaling" at the Max Planck Institute of Biochemistry has been elected member of the German National Academy of Sciences Leopoldina. Brenda Schulman, director at the Max Planck Institute of Biochemistry (MPIB), has been elected to Germany’s National Academy of Sciences. Schulman has thus been accepted into the ranks of a community of around 1600 outstanding scientists from Germany and the world over. The election is a special honour and is regarded as one of the highest scientific accolades in the German-speaking world. About the new member Proteins are major constituents of every cell and, because of the many roles they play, are among the most important biochemical agents. Brenda Schulman’s research aims to improve our understanding how protein activities are dynamically controlled during cellular processes. Together with her team, she is investigating the ubiquitin system. Disorders of this system have been implicated in cancer, neurodegenerative diseases and infections. Ubiquitin, a small signal protein, binds to target proteins and controls important biological processes. It acts as a stop signal and can affect the stability of the target protein, its cellular location, its enzyme activity or its interaction with other molecules. In her research, Brenda Schulman investigates how, and especially when, ubiquitin binds to target proteins with a view to counteracting potential dysregulation. Schulman studied biology at Johns Hopkins University, Baltimore, MD, USA.
    [Show full text]
  • Press Release, April 16, 2018 Advanced ERC Grant for Brenda
    public relations Press Release, April 16, 2018 dr. christiane menzfeld tel.: +49 89 8578-2824 [email protected] www.biochem.mpg.de/news @MPI_Biochem Advanced ERC Grant for Brenda Schulman Brenda Schulman, head of the department „Molecular Machines and Signaling“ at the Max Planck Institute of Biochemistry in Martinsried receives the Advanced Grant of the European Research Council. It comes with a funding of 2.2 million Euros over five years. Together with her team, Schulman wants to find out the numerous ways the ubiquitin-like protein NEDD8 activates hundreds of distinct but related ubiquitin ligase machineries. The understanding of these protein machineries on structural, functional, and cellular levels will help to understand a large family of regulatory complexes that control a major part of eukaryotic biology, like immunity or cell division and thereby plays a central role in many diseases. Proteins are the workhorses of cells. Different types of work are done by different types of proteins, ranging from enzymes that digest food to components of muscle. In order for proteins to work properly, they need to be switched on when needed and off when their jobs are done. A major way that proteins are switched off is by marking them with another small protein called “ubiquitin”. Just like there are many different proteins, there are also hundreds of different molecular machines called E3 ligases that execute tagging with ubiquitin. Therefore, it is essential that E3 ligases are themselves turned on and off at the right place and at the right time in cells. The “on-switch” for about one-third of all E3 ligases is a small protein that looks like ubiquitin, but is called NEDD8.
    [Show full text]
  • Brenda A. Schulman, PH.D
    SPONSORED BY: DEPARTMENT OF BIOCHEMISTRY & CENTER FOR STRUCTURAL BIOLOGY LUBOMIR S. HNILICA LECTURESHIP BRENDA A. SCHULMAN, PH.D TWISTS AND TURNS IN UBIQUITIN CONJUGATION CASCADES JANUARY 10, 2013 4:00 P.M. 208 LIGHT HALL Upcoming Discovery Lecture: ANDREW Z. FIRE, PH.D. Stanford University January 24, 2013 208 Light Hall / 4:00 P.M. TWISTS AND TURNS IN UBIQUITIN CONJUGATION CASCADES Post-translational modification by ubiquitin-like proteins (UBLs) is a predominant eukaryotic regulatory mechanism. The vast reach of this BRENDA A. SCHULMAN form of regulation extends to virtually all eukaryotic processes that in- MEMBER OF THE DEPARTMENTS OF STRUCTURAL BIOLOGY AND GENETICS/TUMOR CELL BIOLOGY volve proteins. UBL modifications play critical roles in controlling the cell ST. JUDE Children’s RESEARCH HOSPITAL cycle, transcription, DNA repair, stress responses, signaling, immunity, CO-DIRECTOR OF THE PROGRAM IN MOLECULAR ONCOLOGY plant growth, embryogenesis, circadian rhythms, and a plethora of other ST. JUDE COMPREHENSIVE CANCER CENTER pathways. UBLs dynamically modulate target protein properties includ- INVESTIGATOR HOWARD HUGHES MEDICAL INSTITUTE ing enzymatic activity, conformation, half-life, subcellular localization, and intermolecular interactions. Moreover, the enzymatic process of UBL ligation to proteins is itself dynamic, involving cascades of E1, E2, and E3 enzymes. The UBL C-terminus is first activated, then transferred between Brenda Schulman is an Investigator of the Howard Hughes Medical multiple enzyme active sites, and ultimately ligated via an E3 enzyme to a Institute, and a Member at St. Jude Children’s Research Hospital. She is target. With roughly 300 members, the largest E3 family consists of Cullin- also Co-Director of the Program in Molecular Oncology at the St.
    [Show full text]
  • Asbmbtoday-2014-06.Pdf
    Vol. 13 / No. 6 / June/July 2014 THE MEMBER MAGAZINE OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY CONTENTS NEWS FEATURES PERSPECTIVES 2 24 32 PRESIDENT’S MESSAGE VITAMIN D CAREER INSIGHTS A president’s perspective How much is enough? 32 Location, location, location! on Experimental Biology 2014 33 e cool professor 5 6 34 Quick guide to career fairs ANNUAL MEETING 36 5 Experimental Biology 2014 tweet analysis MENTORING 6 Scenes from the annual meeting e measure of success 9 38 NEWS FROM THE HILL OPEN LETTERS A challenge reissued e road to professor 10 40 MEMBER UPDATE 38 OUTREACH 11 New members of the American Science-communication training Academy of Arts & Sciences for graduate students 12 44 NEWS OPEN CHANNELS ASBMB wins two NSF grants Reader comments to support teachers and students 14 20 9 JOURNAL NEWS 18 LIPID NEWS Intracellular lipid transport 20 RETROSPECTIVE Malcolm Daniel Lane Sr. (1930–2014) 24 14 Science writer Rajendrani Mukhopadhyay explores the debate over how much vitamin D is enough for good health. JUNE/JULY 2014 ASBMB TODAY 1 PRESIDENT’S MESSAGE tary appeared in the Proceedings of exploring the possibilities of strategic the National Academy of Sciences, use of these tools and even attended THE MEMBER MAGAZINE OF THE AMERICAN SOCIETY written by Bruce Alberts, Marc a breakfast meeting built around a FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY A president’s Kirschner, Shirley Tilghman and Twitter tutorial. Harold Varmus, titled “Rescuing U.S. ASBMB sta and others used OFFICERS COUNCIL MEMBERS biomedical research from its systemic Twitter as a useful tool for highlight- SUMMERS HRABOWSKI Steven McKnight Squire J.
    [Show full text]